M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism.

Humans Leukemia, Myeloid, Acute / pathology Macrophages / pathology Phagocytosis Immunohistochemistry Tumor Microenvironment

Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
14 04 2023
Historique:
medline: 18 4 2023
entrez: 14 4 2023
pubmed: 15 4 2023
Statut: ppublish

Résumé

It is increasingly becoming clear that cancers are a symbiosis of diverse cell types and tumor clones. Combined single-cell RNA sequencing, flow cytometry, and immunohistochemistry studies of the innate immune compartment in the bone marrow of patients with acute myeloid leukemia (AML) reveal a shift toward a tumor-supportive M2-polarized macrophage landscape with an altered transcriptional program, with enhanced fatty acid oxidation and NAD

Identifiants

DOI: 10.1126/sciadv.adf8522 PMID: 37058562
pubmed: 37058562
doi: 10.1126/sciadv.adf8522
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadf8522

Auteurs

Isabel Weinhäuser (I)

Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
Department of Internal Medicine, Medical School of Ribeirao Preto, University of São Paulo, Ribeirao Preto, Brazil.
Center for Cell Based Therapy, University of São Paulo, Ribeirao Preto, Brazil.
ORCID: 0000-0002-6238-2783

Diego A Pereira-Martins (DA)

Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
Department of Internal Medicine, Medical School of Ribeirao Preto, University of São Paulo, Ribeirao Preto, Brazil.
Center for Cell Based Therapy, University of São Paulo, Ribeirao Preto, Brazil.
ORCID: 0000-0002-3302-4311

Luciana Y Almeida (LY)

Department of Internal Medicine, Medical School of Ribeirao Preto, University of São Paulo, Ribeirao Preto, Brazil.
ORCID: 0000-0001-5403-4052

Jacobien R Hilberink (JR)

Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
ORCID: 0000-0003-3726-8935

Douglas R A Silveira (DRA)

Myeloid Leukaemia Genomics and Biology Group, School of Cancer and Pharmaceutical Sciences, King's College London, London, SE5 8AF, UK.
ORCID: 0000-0001-5298-9592

Lynn Quek (L)

Myeloid Leukaemia Genomics and Biology Group, School of Cancer and Pharmaceutical Sciences, King's College London, London, SE5 8AF, UK.
ORCID: 0000-0003-0221-5761

Cesar Ortiz (C)

Department of Internal Medicine, Medical School of Ribeirao Preto, University of São Paulo, Ribeirao Preto, Brazil.
Center for Cell Based Therapy, University of São Paulo, Ribeirao Preto, Brazil.
ORCID: 0000-0003-3420-803X

Cleide L Araujo (CL)

Department of Internal Medicine, Medical School of Ribeirao Preto, University of São Paulo, Ribeirao Preto, Brazil.
ORCID: 0000-0002-7841-3652

Thiago M Bianco (TM)

Department of Internal Medicine, Medical School of Ribeirao Preto, University of São Paulo, Ribeirao Preto, Brazil.

Antonio Lucena-Araujo (A)

Department of Genetics, Federal University of Pernambuco, Recife, Brazil.
ORCID: 0000-0003-1694-8958

Jose Mauricio Mota (JM)

Medical Oncology Service, Sao Paulo State Cancer Institute, University of Sao Paulo, Brazil.
ORCID: 0000-0001-9510-6956

Shanna M Hogeling (SM)

Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
ORCID: 0000-0003-2124-5333

Dominique Sternadt (D)

Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
ORCID: 0000-0003-3946-1368

Nienke Visser (N)

Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.

Arjan Diepstra (A)

Department of Pathology and Medical Biology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
ORCID: 0000-0001-9239-1050

Emanuele Ammatuna (E)

Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
ORCID: 0000-0001-8247-4901

Gerwin Huls (G)

Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.

Eduardo M Rego (EM)

Center for Cell Based Therapy, University of São Paulo, Ribeirao Preto, Brazil.
ORCID: 0000-0003-1567-4086

Jan Jacob Schuringa (JJ)

Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
ORCID: 0000-0001-8452-8555

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › M2 macrophages drive leukemic transformation...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › M2 macrophages drive leukemic transformation...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Macrophages › M2 macrophages drive leukemic transformation...
questionsmedicales.fr › Phénomènes du système immunitaire › Phagocytose › M2 macrophages drive leukemic transformation...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Immunohistochimie › M2 macrophages drive leukemic transformation...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › M2 macrophages drive leukemic transformation...